Eimad Shotar, Bertrand Mathon, Aymeric Rouchaud, Charbel Mounayer, Henri Salle, Nicolas Bricout, Jean-Paul Lejeune, Kevin Janot, Ilyess Zemmoura, Olivier Naggara, Alexandre Roux, Stéphane Goutagny, Alexis Guedon, Herve Brunel, Lucas Troude, Henry Dufour, Anne-Laure Bernat, Titien Tuilier, Damien Bresson, Caroline Apra, Mathilde Fouet, Simon Escalard, Dorian Chauvet, Amandine Baptiste, Said Lebbah, Agnès Dechartres, Frédéric Clarençon
BACKGROUND: Middle meningeal artery (MMA) embolization has been proposed as a treatment of chronic subdural hematoma (CSDH). The benefit of the procedure has yet to be demonstrated in a randomized controlled trial. We aim to assess the efficacy of MMA embolization in reducing the risk of CSDH recurrence 6 months after burr-hole surgery compared with standard medical treatment in patients at high risk of postoperative recurrence. METHODS: The EMPROTECT trial is a multicenter open label randomized controlled trial (RCT) involving 12 French centers...
February 2, 2024: Journal of Neurointerventional Surgery